Oramed Pharmaceuticals Inc. (ORMP)

4.01
0.07 1.72
NASDAQ : Health Technology
Prev Close 4.08
Open 4.09
Day Low/High 4.00 / 4.14
52 Wk Low/High 3.91 / 9.48
Volume 18.68K
Avg Volume 24.00K
Exchange NASDAQ
Shares Outstanding 17.38M
Market Cap 70.21M
EPS -0.90
P/E Ratio 4.70
Div & Yield N.A. (N.A)

Latest News

Oramed Enrolls First Patient In Its Clinical Study For Oral Insulin In The Treatment Of NASH

Oramed Enrolls First Patient In Its Clinical Study For Oral Insulin In The Treatment Of NASH

NEW YORK, Oct. 4, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

Oramed Receives FDA Clearance For IND Application For Its Oral GLP-1 Analog Capsule

Oramed Receives FDA Clearance For IND Application For Its Oral GLP-1 Analog Capsule

NEW YORK, Sept. 17, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

Oramed To Present At The H.C. Wainwright Global Investment Conference

Oramed To Present At The H.C. Wainwright Global Investment Conference

NEW YORK, Aug. 28, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc.

Oramed Granted Japanese Patent For GLP-1 Analog Capsule

Oramed Granted Japanese Patent For GLP-1 Analog Capsule

NEW YORK, July 24, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.

Oramed Announces Closing Of $18.1 Million Registered Direct Offering

Oramed Announces Closing Of $18.1 Million Registered Direct Offering

NEW YORK, July 6, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the closing of its previously-announced...

Oramed Announces $18.1 Million Registered Direct Offering

Oramed Announces $18.1 Million Registered Direct Offering

NEW YORK, July 3, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has entered into definitive...

Oramed Enrolls First Patient In Its Glucose Clamp Study For Oral Insulin

Oramed Enrolls First Patient In Its Glucose Clamp Study For Oral Insulin

Study will provide additional metabolic data on ORMD-0801 in patients with type 1 diabetes

Oramed Initiates Food Effect Study For Its Oral Insulin Capsule ORMD-0801

Oramed Initiates Food Effect Study For Its Oral Insulin Capsule ORMD-0801

NEW YORK, June 21, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.

Oramed To Be Added To Russell Microcap® Index

Oramed To Be Added To Russell Microcap® Index

NEW YORK, June 19, 2018 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) ( www.

Relative Strength Alert For Oramed Pharmaceuticals

Relative Strength Alert For Oramed Pharmaceuticals

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,200 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATRO, BLL, CCE, CSII, EGN, EMR, HCI, IMPV, K, MANT, MLCO, MX, OI, RDS.A, RDS.B, TPRE, USCR, WMC Downgrades: CCO, CLF, GCAP, INCY, KMPR, OMCL, OMI, SHEN, SWIR, UEPS Initiations: ORMP Read on to get TheStreet Quant Ratings' detailed report:

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) Stock Surges on $50 Million Chinese Licensing Deal

Oramed Pharmaceuticals (ORMP) stock is rising on heavy volume trading on Monday after the clinical-stage pharmaceutical company announced a $50 million licensing deal in China.

3 Stocks Under $10 to Trade for Breakouts

3 Stocks Under $10 to Trade for Breakouts

These under-$10 stocks are within range of triggering breakout trades.

3 Stocks Under $10 Triggering Breakout Trades

3 Stocks Under $10 Triggering Breakout Trades

These under-$10 stocks are within range of triggering big breakout trades.

A Speculative Biotech Catalyst Trade: ORMP

A Speculative Biotech Catalyst Trade: ORMP

This beaten-down biotech stock could be ripe for a rebound.

5 Stocks With Big Insider Buying

5 Stocks With Big Insider Buying

Insiders at these companies have been scooping up shares of their own stock lately.

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

These Stocks Are Getting Hit Hardest During March's Biotech 'Correction'

Geron, Celldex Therapeutics, Xoma and Cytrx are among the drug stocks losing more than 30% of their value in the past month.

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech Stock Mailbag: Raptor, Chelsea, Oncogenex, More Hate Mail!

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Oramed's Oral Insulin Pill Data 'Completely Worthless'

Oramed's Oral Insulin Pill Data 'Completely Worthless'

Oramed hyped results from an insulin pill safety study, then made it difficult to find the actual data.

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown

Biotech Stock Mailbag: Cell Therapeutics and the Ariad Hostile React-o-Meter Meltdown

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better

Biotech Trading 2014 Starts Hot, But Surprise, Last Year Was Even Better

The biotech sector has jumped off to a strong start to 2014, with today's blockbuster move in Intercept Pharma offering a big assist. I know it's ridiculously early to make any sort of definitive judgment, but I wondered how the first days of biotech trading 2014 compared to 2013. Here are the charts:

[video] Quick Take: Revolutionizing Diabetes Treatment

[video] Quick Take: Revolutionizing Diabetes Treatment

This biotech company is seeking to revolutionize the treatment of diabetes. Nadav Kidron reviews Oramed's proprietary product.

Seeking to Remake Diabetes Therapy

Seeking to Remake Diabetes Therapy

This biotech company is seeking to revolutionize the treatment of diabetes. Nadav Kidron reviews Oramed's proprietary product.

Oramed Pharmaceuticals Granted Israeli Patent For Its Core Technology In Oral Delivery Of Proteins

Oramed Pharmaceuticals Granted Israeli Patent For Its Core Technology In Oral Delivery Of Proteins

Marking a major milestone for the company, Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Awarded Grant By The Office Of The Chief Scientist Of Israel

Oramed Pharmaceuticals Awarded Grant By The Office Of The Chief Scientist Of Israel

Oramed Pharmaceuticals Inc. (OTCBB: ORMP) ( http://www.

TheStreet Quant Rating: D- (Sell)